Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2018-2033)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Region
2.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2024-2033)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2018-2023)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2022
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2024-2033)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2018-2033)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2018-2033)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2018-2033)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2018-2033)
9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023)
9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2018-2033)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Detail
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Detail
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Detail
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.3.5 Fresenius Kabi AG Recent Development
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Detail
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Detail
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.5.5 Lupin Ltd. Recent Development
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Detail
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Development
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Detail
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Development
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Detail
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.8.5 Sandoz Inc. (Novartis) Recent Development
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Detail
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.9.5 Alkem Laboratories Ltd. Recent Development
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Detail
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Development
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Detail
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Detail
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.12.5 MedImmune LLC Recent Development
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Detail
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
11.13.5 RemeGen, Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Eculizumab
Table 3. Key Players of Methylprednisolone
Table 4. Key Players of Azathioprine
Table 5. Key Players of Mycophenolate Mofetil
Table 6. Key Players of Rituximab
Table 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2018-2023)
Table 11. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2024-2033)
Table 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
Table 14. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
Table 15. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
Table 16. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2018-2023)
Table 19. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2022)
Table 20. Ranking of Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
Table 24. Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2018-2023)
Table 28. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2024-2033)
Table 30. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2018-2023)
Table 32. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2024-2033)
Table 34. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2024-2033) & (US$ Million)
Table 49. Alexion Pharmaceuticals, Inc. Company Detail
Table 50. Alexion Pharmaceuticals, Inc. Business Overview
Table 51. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 52. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 53. Alexion Pharmaceuticals, Inc. Recent Development
Table 54. Teva Pharmaceuticals Company Detail
Table 55. Teva Pharmaceuticals Business Overview
Table 56. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 57. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 58. Teva Pharmaceuticals Recent Development
Table 59. Fresenius Kabi AG Company Detail
Table 60. Fresenius Kabi AG Business Overview
Table 61. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 62. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 63. Fresenius Kabi AG Recent Development
Table 64. Pharmacia & Upjohn (a subsidary of Pfizer) Company Detail
Table 65. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
Table 66. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 67. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 68. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
Table 69. Lupin Ltd. Company Detail
Table 70. Lupin Ltd. Business Overview
Table 71. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 72. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 73. Lupin Ltd. Recent Development
Table 74. Sagent Pharmaceuticals, Inc. Company Detail
Table 75. Sagent Pharmaceuticals, Inc. Business Overview
Table 76. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 77. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 78. Sagent Pharmaceuticals, Inc. Recent Development
Table 79. Zydus Pharmaceuticals, Inc. Company Detail
Table 80. Zydus Pharmaceuticals, Inc. Business Overview
Table 81. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 82. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 83. Zydus Pharmaceuticals, Inc. Recent Development
Table 84. Sandoz Inc. (Novartis) Company Detail
Table 85. Sandoz Inc. (Novartis) Business Overview
Table 86. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 87. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 88. Sandoz Inc. (Novartis) Recent Development
Table 89. Alkem Laboratories Ltd. Company Detail
Table 90. Alkem Laboratories Ltd. Business Overview
Table 91. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 92. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 93. Alkem Laboratories Ltd. Recent Development
Table 94. Mylan Pharmaceuticals, Inc. Company Detail
Table 95. Mylan Pharmaceuticals, Inc. Business Overview
Table 96. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 97. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 98. Mylan Pharmaceuticals, Inc. Recent Development
Table 99. Hoffmann-La Roche/ Chugai Pharmaceutical Company Detail
Table 100. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
Table 101. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 102. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 103. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
Table 104. MedImmune LLC Company Detail
Table 105. MedImmune LLC Business Overview
Table 106. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 107. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 108. MedImmune LLC Recent Development
Table 109. RemeGen, Ltd. Company Detail
Table 110. RemeGen, Ltd. Business Overview
Table 111. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 112. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023) & (US$ Million)
Table 113. RemeGen, Ltd. Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2022 VS 2033
Figure 3. Eculizumab Features
Figure 4. Methylprednisolone Features
Figure 5. Azathioprine Features
Figure 6. Mycophenolate Mofetil Features
Figure 7. Rituximab Features
Figure 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2022 VS 2033
Figure 10. Hospitals Case Studies
Figure 11. Clinic Case Studies
Figure 12. Others Case Studies
Figure 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region: 2022 VS 2033
Figure 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2022
Figure 18. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2022
Figure 20. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2018-2033)
Figure 22. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2018-2033)
Figure 26. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2018-2033)
Figure 34. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2018-2033)
Figure 42. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2018-2033)
Figure 46. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 49. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 50. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 51. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 52. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 53. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 54. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 55. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 56. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 57. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 58. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 59. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 60. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2018-2023)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed